Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin Dose Comparison for LV Remodeling in Diabetic Anterior STEMI
NCT07169981Phase 2Completed
- Sponsor
- Ain Shams University
- Start
- Jul 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of empagliflozin in heart failure with reduced ejection fraction (HFrEF), sponsored by Ain Shams University. Started Jul 2023; status: completed.
02
Drugs
empagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT07169981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07169981.